## 1) “Definitive” here means *contracted, financed, and already on the regulatory clock* Danaher disclosed that it has signed an **Agreement and Plan of Merger dated February 16, 2026**, under which it will **acquire all outstanding Masimo shares for $180.00 per share in cash** and merge a wholly owned subsidiary into Masimo, leaving Masimo as the surviving company and a **wholly owned subsidiary** post-close. ["Agreement and Plan of Merger"](0001193125-26-053124|0) ["$180.00 per share"](0001193125-26-053124|0) ["wholly owned subsidiary"](0001193125-26-053124|0) The gating items Danaher explicitly calls out are *process*, not *price*: the deal is conditioned on **HSR waiting period expiration** plus certain **non-U.S. antitrust and foreign direct investment approvals**—a tell that the core question is timing/clearances rather than renegotiation risk. ["Hart-Scott-Rodino"](0001193125-26-053124|0) ["foreign direct investment approvals"](0001193125-26-053124|0) ## 2) The “standalone operating company” language signals a disciplined integration play—DBS leverage without brand dilution Danaher is positioning Masimo to remain a **standalone operating company within its Diagnostics segment**, alongside major established operating companies—suggesting a playbook of operational enhancement and distribution scaling rather than a disruptive integration that could jeopardize clinical adoption or customer trust. ["standalone operating company"](0001193125-26-053124|1) ["within Danaher’s Diagnostics segment"](0001193125-26-053124|1) Between the lines, that matters because it frames where the alpha is likely to come from: Danaher is implicitly underwriting that the product/brand equity is already strong—and that its edge is *execution at scale*. ["Danaher Business System"](0001193125-26-053124|1) ["expand Masimo’s reach"](0001193125-26-053124|1) ## 3) What Danaher is really buying: a monitoring + sensor + AI wedge into acute-care decisioning Danaher characterizes Masimo as a leader in **pulse oximetry and other patient monitoring solutions** in **acute care settings**, and separately highlights **advanced sensor technology and AI-enabled monitoring** as additive capabilities for its Diagnostics portfolio. ["pulse oximetry and other patient monitoring"](0001193125-26-053124|1) ["acute care settings"](0001193125-26-053124|1) ["AI-enabled monitoring"](0001193125-26-053124|1) The subtext: this is less about “another device company” and more about expanding Danaher’s footprint into real-time clinical workflows—where recurring consumables, installed base, software, and service attach can compound over time if Danaher successfully industrializes go-to-market globally. ["strengthen our diagnostics franchise"](0001193125-26-053124|1) ["global scale"](0001193125-26-053124|1) ## 4) The hidden financial tell: Danaher is underwriting *multi-year earnings power*, not just a 2026 close Danaher discloses the deal is expected to be **accretive to adjusted EPS by $0.15–$0.20 in the first full year**, rising to **~$0.70 by the fifth full year**—which reads like a management team confident it can compound operational improvements and synergy capture well beyond “day one.” ["accretive to adjusted diluted"](0001193125-26-053124|1) ["approximately $0.70"](0001193125-26-053124|1) They also put stakes in the ground on synergy and earnings capacity: **> $530 million of EBITDA in 2027**, with **> $125 million annual cost synergies** and **> $50 million annual revenue synergies** by year five—explicitly framing a path where the multiple compresses as execution converts “good assets” into “Danaher assets.” ["EBITDA of more than $530 million"](0001193125-26-053124|1) ["more than $125 million"](0001193125-26-053124|1) ["more than $50 million"](0001193125-26-053124|1) Finally, Danaher signals valuation discipline and confidence by citing an **~18x estimated 2027 EBITDA** entry multiple (or **~15x including full expected synergies**)—the kind of disclosure that effectively invites investors to underwrite the integration math alongside management. ["approximately 18x estimated 2027 EBITDA"](0001193125-26-053124|1) ["15x 2027 estimated EBITDA"](0001193125-26-053124|1) ## 5) Near-term catalyst map: expect “process milestones,” not quarterly storytelling Danaher states the transaction is anticipated to **close in the second half of 2026**, subject to regulatory clearances and Masimo shareholder approval—so the tradable milestones are likely to be (i) filing of merger materials/proxy, (ii) antitrust/FDI progress, and (iii) financing finalization rather than incremental narrative in quarterly calls. ["close in the second half of 2026"](0001193125-26-053124|1) ["Masimo shareholder approval"](0001193125-26-053124|1) ["regulatory clearances"](0001193125-26-053124|1) Danaher also discloses expected funding sources—**cash on hand plus debt financing**—which reduces ambiguity about “how it gets done” and shifts the market’s focus to clearance timing and integration delivery. ["cash on hand"](0001193125-26-053124|1) ["proceeds from debt financing"](0001193125-26-053124|1)

## 1) “Definitive” here means *contracted, financed, and already on the regulatory clock* Danaher disclosed that it has signed an **Agreement and Plan of Merger dated February 16, 2026**, under which it will **acquire all outstanding Masimo shares for $180.00 per share in cash** and merge a wholly owned subsidiary into Masimo, leaving Masimo as the surviving company and a **wholly owned subsidiary** post-close. ["Agreement and Plan of Merger"](0001193125-26-053124|0) ["$180.00 per share"](0001193125-26-053124|0) ["wholly owned subsidiary"](0001193125-26-053124|0) The gating items Danaher explicitly calls out are *process*, not *price*: the deal is conditioned on **HSR waiting period expiration** plus certain **non-U.S. antitrust and foreign direct investment approvals**—a tell that the core question is timing/clearances rather than renegotiation risk. ["Hart-Scott-Rodino"](0001193125-26-053124|0) ["foreign direct investment approvals"](0001193125-26-053124|0) ## 2) The “standalone operating company” language signals a disciplined integration play—DBS leverage without brand dilution Danaher is positioning Masimo to remain a **standalone operating company within its Diagnostics segment**, alongside major established operating companies—suggesting a playbook of operational enhancement and distribution scaling rather than a disruptive integration that could jeopardize clinical adoption or customer trust. ["standalone operating company"](0001193125-26-053124|1) ["within Danaher’s Diagnostics segment"](0001193125-26-053124|1) Between the lines, that matters because it frames where the alpha is likely to come from: Danaher is implicitly underwriting that the product/brand equity is already strong—and that its edge is *execution at scale*. ["Danaher Business System"](0001193125-26-053124|1) ["expand Masimo’s reach"](0001193125-26-053124|1) ## 3) What Danaher is really buying: a monitoring + sensor + AI wedge into acute-care decisioning Danaher characterizes Masimo as a leader in **pulse oximetry and other patient monitoring solutions** in **acute care settings**, and separately highlights **advanced sensor technology and AI-enabled monitoring** as additive capabilities for its Diagnostics portfolio. ["pulse oximetry and other patient monitoring"](0001193125-26-053124|1) ["acute care settings"](0001193125-26-053124|1) ["AI-enabled monitoring"](0001193125-26-053124|1) The subtext: this is less about “another device company” and more about expanding Danaher’s footprint into real-time clinical workflows—where recurring consumables, installed base, software, and service attach can compound over time if Danaher successfully industrializes go-to-market globally. ["strengthen our diagnostics franchise"](0001193125-26-053124|1) ["global scale"](0001193125-26-053124|1) ## 4) The hidden financial tell: Danaher is underwriting *multi-year earnings power*, not just a 2026 close Danaher discloses the deal is expected to be **accretive to adjusted EPS by $0.15–$0.20 in the first full year**, rising to **~$0.70 by the fifth full year**—which reads like a management team confident it can compound operational improvements and synergy capture well beyond “day one.” ["accretive to adjusted diluted"](0001193125-26-053124|1) ["approximately $0.70"](0001193125-26-053124|1) They also put stakes in the ground on synergy and earnings capacity: **> $530 million of EBITDA in 2027**, with **> $125 million annual cost synergies** and **> $50 million annual revenue synergies** by year five—explicitly framing a path where the multiple compresses as execution converts “good assets” into “Danaher assets.” ["EBITDA of more than $530 million"](0001193125-26-053124|1) ["more than $125 million"](0001193125-26-053124|1) ["more than $50 million"](0001193125-26-053124|1) Finally, Danaher signals valuation discipline and confidence by citing an **~18x estimated 2027 EBITDA** entry multiple (or **~15x including full expected synergies**)—the kind of disclosure that effectively invites investors to underwrite the integration math alongside management. ["approximately 18x estimated 2027 EBITDA"](0001193125-26-053124|1) ["15x 2027 estimated EBITDA"](0001193125-26-053124|1) ## 5) Near-term catalyst map: expect “process milestones,” not quarterly storytelling Danaher states the transaction is anticipated to **close in the second half of 2026**, subject to regulatory clearances and Masimo shareholder approval—so the tradable milestones are likely to be (i) filing of merger materials/proxy, (ii) antitrust/FDI progress, and (iii) financing finalization rather than incremental narrative in quarterly calls. ["close in the second half of 2026"](0001193125-26-053124|1) ["Masimo shareholder approval"](0001193125-26-053124|1) ["regulatory clearances"](0001193125-26-053124|1) Danaher also discloses expected funding sources—**cash on hand plus debt financing**—which reduces ambiguity about “how it gets done” and shifts the market’s focus to clearance timing and integration delivery. ["cash on hand"](0001193125-26-053124|1) ["proceeds from debt financing"](0001193125-26-053124|1)